Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
ALT
#3019
Altimmune, Inc. Common Stock
3.3
9
USD
+3.04%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+3.04%
Changement Mensuel
-5.83%
Evolution sur 6 mois
-15.25%
Changement Annuel
-24.16%
Clôture Précédente
3.2
9
Open
3.3
9
Bid
Ask
Low
3.3
9
High
3.3
9
Volume
7
Marchés
Actions des Marchés US
Soins de Santé
ALT
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
77.01 M
81.11 M
88.26 M
104.25 M
130.07 M
—
Valuation ratios
Enterprise value
518.34 M
356.43 M
172.78 M
346.25 M
460.08 M
1.34 B
Price to earnings ratio
-5.38
-3.97
-3.28
-3.52
-3.61
-14.38
Price to sales ratio
25.6 K
18.02 K
14.42 K
14.85 K
7 757.46
55.05 K
Price to cash flow ratio
-6.41
-4.48
-3.52
-4.43
-4.71
-17.14
Price to book ratio
4.14
0.65
0.52
0.49
1.41
3.08
Enterprise value to EBITDA ratio
-4.85
-3.51
-1.79
-3.76
-4.8
-13.86
Profitability ratios
Return on assets %
-0.17
-0.12
-0.12
-0.09
-0.1
-0.43
Return on equity %
-0.19
-0.14
-0.14
-0.1
-0.12
-0.5
Return on invested capital %
—
-937.74
-1 091.39
-1 172.35
-1 567.5
-4 768.99
Gross margin %
100
100
100
100
100
400
Operating margin %
-497.32 K
-436.3 K
-458.44 K
-417.18 K
-111.13 K
-1.42 M
EBITDA margin %
-513.04 K
-449.44 K
-466.46 K
-418.3 K
-113.79 K
-1.45 M
Net margin %
-463.6 K
-391.5 K
-442.92 K
-380.28 K
-105.22 K
-1.32 M
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
13.11
15.85
20.44
17.18
18.55
72.02
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
0.08
0.07
0.12
—
Debt to equity ratio
—
—
0.09
0.08
0.15
—
Long term debt to total assets ratio
—
—
0.08
0.07
0.12
—
Long term debt to total equity ratio
—
—
0.09
0.08
0.15
—
Per share metrics
Operating cash flow per share
-0.26
-0.22
-0.24
-0.13
-0.22
-0.81
EBIT per share
-0.35
-0.29
-0.28
-0.23
-0.33
-1.13
EBITDA per share
-0.36
-0.3
-0.29
-0.23
-0.34
-1.15
Total debt per share
—
—
0.18
0.16
0.39
—
Cash per share
1.86
1.98
2.25
2.36
3.1
9.69
Net current asset value per share
1.93
2.06
2.31
2.42
3.16
9.95
Tangible book value per share
1.74
1.88
1.98
2.08
2.55
8.49
Working capital per share
1.79
1.93
2.2
2.28
2.99
9.39
Book value per share
1.74
1.88
1.98
2.08
2.55
8.49
Nouvelles
Le directeur Gill d’Altimmune achète pour 31.000$ d’actions
Jefferies réitère sa recommandation d’achat sur Altimmune, maintient l’objectif de 28$
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms
Altimmune Stock: Neutral Outlook With Big 2026 Catalysts
ALT Pemvidutide Explained: What Makes It Different in MASH
Truist initie la couverture d’Altimmune avec une recommandation d’achat
H.C. Wainwright relève l’objectif de cours d’Altimmune sur fond de focus MASH
H.C. Wainwright raises Altimmune stock price target on MASH focus
Altimmune à la conférence Barclays : faire progresser le potentiel du pemvidutide
Altimmune at Barclays Conference: Advancing Pemvidutide’s Potential
Altimmune à la conférence Leerink : avancées stratégiques dans le traitement de la MASH
Altimmune at Leerink Conference: Strategic Advances in MASH Treatment